Browse News
Filter News
Found 304 articles
-
Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision
8/8/2022
Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed.
-
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
8/4/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended June 30, 2022 and recent business highlights.
-
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
8/2/2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality.
-
Coherus BioSciences Announces New Employment Inducement Grants - Aug 02, 2022
8/2/2022
Coherus BioSciences, Inc., announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date.
-
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
-
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
7/28/2022
Coherus BioSciences, Inc., announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022.
-
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
-
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.
7/20/2022
ZyVersa Therapeutics, Inc. ("ZyVersa"), and Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement").
-
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.
-
A cancer drug co-developed by Coherus BioSciences and Junshi Biosciences, toripalimab, is getting another opportunity before the U.S. Food and Drug Administration.
-
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7/5/2022
Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer.
-
Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform
6/22/2022
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent).
-
Coherus BioSciences Announces New Employment Inducement Grants - June 22, 2022
6/22/2022
Coherus BioSciences, Inc., announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date.
-
Ophthalmic Drugs Market Demand 2022-2028: Increasing Number Of Patients Suffering From Glaucoma In Developed And Developing Nations
6/20/2022
Forecast to 2028,’ thoroughly examines the Ophthalmic Drugs industry to provide essential data & information for the targeted readers.
-
Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022
6/7/2022
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company highlighted its pipeline advances in immunotherapy drugs, including anti-PD-1 monoclonal antibody toripalimab and anti-BTLA monoclonal antibody icatolimab (TAB004/JS004).
-
TIGIT Inhibitor Drug Clinical Trials Report 2022
5/20/2022
T-cell immunoreceptor with Ig and ITM domain (TIGIT) is novel immunological checkpoint which is being studied as potential immunotherapeutic target.
-
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma
5/16/2022
Shanghai Junshi Biosciences Co., Ltd announced that the China National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma.
-
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
5/16/2022
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.